205 related articles for article (PubMed ID: 29174389)
1. Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)
Marcovina SM; Viney NJ; Hughes SG; Xia S; Witztum JL; Tsimikas S
J Clin Lipidol; 2018; 12(1):122-129.e2. PubMed ID: 29174389
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Viney NJ; van Capelleveen JC; Geary RS; Xia S; Tami JA; Yu RZ; Marcovina SM; Hughes SG; Graham MJ; Crooke RM; Crooke ST; Witztum JL; Stroes ES; Tsimikas S
Lancet; 2016 Nov; 388(10057):2239-2253. PubMed ID: 27665230
[TBL] [Abstract][Full Text] [Related]
3. Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.
Viney NJ; Yeang C; Yang X; Xia S; Witztum JL; Tsimikas S
J Clin Lipidol; 2018; 12(3):702-710. PubMed ID: 29574075
[TBL] [Abstract][Full Text] [Related]
4. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.
Tsimikas S; Viney NJ; Hughes SG; Singleton W; Graham MJ; Baker BF; Burkey JL; Yang Q; Marcovina SM; Geary RS; Crooke RM; Witztum JL
Lancet; 2015 Oct; 386(10002):1472-83. PubMed ID: 26210642
[TBL] [Abstract][Full Text] [Related]
5. Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis.
Boffa MB; Marar TT; Yeang C; Viney NJ; Xia S; Witztum JL; Koschinsky ML; Tsimikas S
J Lipid Res; 2019 Dec; 60(12):2082-2089. PubMed ID: 31551368
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein(a)-antisense therapy.
Vogt A
Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):51-56. PubMed ID: 30859384
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein(a) Antisense Oligonucleotides: A New Treatment Option for Lowering Elevated Lipoprotein(a)?
Schreml J; Gouni-Berthold I
Curr Pharm Des; 2017; 23(10):1562-1570. PubMed ID: 28128058
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.
Tsimikas S; Karwatowska-Prokopczuk E; Gouni-Berthold I; Tardif JC; Baum SJ; Steinhagen-Thiessen E; Shapiro MD; Stroes ES; Moriarty PM; Nordestgaard BG; Xia S; Guerriero J; Viney NJ; O'Dea L; Witztum JL;
N Engl J Med; 2020 Jan; 382(3):244-255. PubMed ID: 31893580
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives.
Wu MF; Xu KZ; Guo YG; Yu J; Wu Y; Lin LM
Cardiovasc Drugs Ther; 2019 Dec; 33(6):739-748. PubMed ID: 31655942
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein(a) Management: Pharmacological and Apheretic Treatment.
Hanssen R; Gouni-Berthold I
Curr Med Chem; 2017; 24(10):957-968. PubMed ID: 28078998
[TBL] [Abstract][Full Text] [Related]
11. CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects.
Thomas T; Zhou H; Karmally W; Ramakrishnan R; Holleran S; Liu Y; Jumes P; Wagner JA; Hubbard B; Previs SF; Roddy T; Johnson-Levonas AO; Gutstein DE; Marcovina SM; Rader DJ; Ginsberg HN; Millar JS; Reyes-Soffer G
Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1770-1775. PubMed ID: 28729361
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.
Roeseler E; Julius U; Heigl F; Spitthoever R; Heutling D; Breitenberger P; Leebmann J; Lehmacher W; Kamstrup PR; Nordestgaard BG; Maerz W; Noureen A; Schmidt K; Kronenberg F; Heibges A; Klingel R;
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):2019-27. PubMed ID: 27417585
[TBL] [Abstract][Full Text] [Related]
13. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.
Santos RD; Raal FJ; Catapano AL; Witztum JL; Steinhagen-Thiessen E; Tsimikas S
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):689-99. PubMed ID: 25614280
[TBL] [Abstract][Full Text] [Related]
14. Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels.
Nissen SE; Wolski K; Balog C; Swerdlow DI; Scrimgeour AC; Rambaran C; Wilson RJ; Boyce M; Ray KK; Cho L; Watts GF; Koren M; Turner T; Stroes ES; Melgaard C; Campion GV
JAMA; 2022 May; 327(17):1679-1687. PubMed ID: 35368052
[TBL] [Abstract][Full Text] [Related]
15. Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a).
Stiekema LCA; Prange KHM; Hoogeveen RM; Verweij SL; Kroon J; Schnitzler JG; Dzobo KE; Cupido AJ; Tsimikas S; Stroes ESG; de Winther MPJ; Bahjat M
Eur Heart J; 2020 Jun; 41(24):2262-2271. PubMed ID: 32268367
[TBL] [Abstract][Full Text] [Related]
16. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice.
Merki E; Graham M; Taleb A; Leibundgut G; Yang X; Miller ER; Fu W; Mullick AE; Lee R; Willeit P; Crooke RM; Witztum JL; Tsimikas S
J Am Coll Cardiol; 2011 Apr; 57(15):1611-21. PubMed ID: 21474042
[TBL] [Abstract][Full Text] [Related]
17. Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype.
Artemeva NV; Safarova MS; Ezhov MV; Afanasieva OI; Dmitrieva OA; Pokrovsky SN
Atheroscler Suppl; 2015 May; 18():53-8. PubMed ID: 25936305
[TBL] [Abstract][Full Text] [Related]
18. Lp(a): Addressing a Target for Cardiovascular Disease Prevention.
Vasquez N; Joshi PH
Curr Cardiol Rep; 2019 Jul; 21(9):102. PubMed ID: 31367887
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen.
Karwatowska-Prokopczuk E; Clouet-Foraison N; Xia S; Viney NJ; Witztum JL; Marcovina SM; Tsimikas S
Atherosclerosis; 2021 May; 324():102-108. PubMed ID: 33872986
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study.
Kollerits B; Drechsler C; Krane V; Lamina C; März W; Dieplinger H; Ritz E; Wanner C; Kronenberg F;
Nephrol Dial Transplant; 2016 Nov; 31(11):1901-1908. PubMed ID: 26754832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
